Effectiveness and safety of oral HIV preexposure prophylaxis for all populations - Wikidata - awgldk - TriplyDB

Effectiveness and safety of oral HIV preexposure prophylaxis for all populations

Effectiveness and safety of oral HIV preexposure prophylaxis for all populations

http://www.wikidata.org/entity/Q34677217

about

Risks associated with lentiviral vector exposures and prevention strategies Pre-exposure Prophylaxis for HIV Prevention: Why, What, Who and How Drug safety evaluation of oral tenofovir disoproxil fumarate-emtricitabine for pre-exposure prophylaxis for human immunodeficiency virus infection.Pre-exposure prophylaxis for HIV prevention in women: current perspectives HIV disease progression among women following seroconversion during a tenofovir-based HIV prevention trial Tenofovir Pre-exposure Prophylaxis for Pregnant and Breastfeeding Women at Risk of HIV Infection: The Time is Now.PrEP implementation research in Africa: what is new?Beyond the 90-90-90: refocusing HIV prevention as part of the global HIV response.Pre-Exposure Prophylaxis (PrEP) as an Additional Tool for HIV Prevention Among Men Who Have Sex With Men in Belgium: The Be-PrEP-ared Study Protocol.Modelling the evolution of HIV-1 virulence in response to imperfect therapy and prophylaxis Values and Preferences on the Use of Oral Pre-exposure Prophylaxis (PrEP) for HIV Prevention Among Multiple Populations: A Systematic Review of the Literature.Feasibility, Acceptability And Adherence With Short Term Hiv Pre-Exposure Prophylaxis In Female Sexual Partners Of Migrant Miners In Mozambique.A Review of HIV Pre-Exposure Prophylaxis: The Female Perspective Clinical and public health implications of acute and early HIV detection and treatment: a scoping review.Offering pre-exposure prophylaxis for HIV prevention to pregnant and postpartum women: a clinical approach The future of pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection."Support Your Client at the Space That They're in": HIV Pre-Exposure Prophylaxis (PrEP) Prescribers' Perspectives on PrEP-Related Risk Compensation.The effect of oral preexposure prophylaxis on the progression of HIV-1 seroconversion.HIV and Bone Complications: Understudied Populations and New Management Strategies.HIV preexposure prophylaxis for adolescents and young adults.Intracellular Tenofovir and Emtricitabine Anabolites in Genital, Rectal, and Blood Compartments from First Dose to Steady State.Willingness to use pre-exposure prophylaxis for HIV prevention among men who have sex with men in Malaysia: Findings from an online survey.The impact of HIV infection and socioeconomic factors on the incidence of gonorrhea: A county-level, US-wide analysis.Newly Acquired Infection with Multi-Drug Resistant HIV-1 in a Patient Adherent to Pre-Exposure Prophylaxis.Preexposure prophylaxis for men who have sex with men and transgender persons in early adopting countries: a narrative review.From intention to STI prevention: An online questionnaire on barriers and facilitators for discussing sexual risk behaviour among HIV nurses.Tackling HIV and AIDS: contributions by non-human primate models.Evaluation of a Multidrug Assay for Monitoring Adherence to a Regimen for HIV Preexposure Prophylaxis in a Clinical Study, HIV Prevention Trials Network 073.Characterization of HIV Seroconverters in a TDF/FTC PrEP Study: HPTN 067/ADAPT.Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelines Validation of participant eligibility for pre-exposure prophylaxis: Baseline data from the PRELUDE demonstration project.When are declines in condom use while using PrEP a concern? Modelling insights from a Hillbrow, South Africa case study.High Burden of HIV, Syphilis and HSV-2 and Factors Associated with HIV Infection Among Female Sex Workers in Tanzania: Implications for Early Treatment of HIV and Pre-exposure Prophylaxis (PrEP).Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy: the DOT-DBS Study.Predictors of HIV, HIV Risk Perception, and HIV Worry Among Adolescent Girls and Young Women in Lilongwe, Malawi.Potential Healthcare Insurance and Provider Barriers to Pre-Exposure Prophylaxis Utilization Among Young Men Who Have Sex with Men.Facilitators and Barriers to Pre-Exposure Prophylaxis Willingness Among Young Men Who Have Sex with Men Who Use Geosocial Networking Applications in California.HIV pre-exposure prophylaxis and early antiretroviral treatment among female sex workers in South Africa: Results from a prospective observational demonstration project.Motivations and barriers to uptake and use of female-initiated, biomedical HIV prevention products in sub-Saharan Africa: an adapted meta-ethnography.PrEP Awareness, Familiarity, Comfort, and Prescribing Experience among US Primary Care Providers and HIV Specialists.

P2860

Q28065064-BEFBCF9F-6F7B-455C-B89E-39BBAE9AA747 Q28080301-C2BC427E-BF9C-4488-98A1-CEE9FAF867DB Q30249113-7D276F28-6831-4BFC-A9D0-56F0E5E52E47 Q33766562-6E316D75-8ADF-4F06-83D1-DE40E2E3A74A Q33848307-A1932EBA-F891-4511-A3E4-84E9EA479EAB Q36146022-5E58CE7E-BF22-42EB-AC15-91A68815E4B0 Q37352576-403B2349-C367-40D1-8024-92FF088D79C3 Q37512411-70BFE220-FD73-4E09-9D76-EB4BC181384F Q37639989-9E397B3C-3B2C-4BEF-B026-D01B4C598BC6 Q37661125-D5A33C88-19AB-4609-B25E-A3A243FC5850 Q37736077-AF5FE438-C347-48AB-AFE2-BA47D205D191 Q38641084-BD2F89CE-3BF2-4B4F-9BD6-D536A6EDF947 Q38672579-B93D8EC5-7B18-4727-9B49-178AA3FAB048 Q38686953-3D986420-3F44-413E-97E0-79CED1C03418 Q38737364-6111B71B-5854-4B2F-80D1-78DDE99C592D Q38742497-6314706D-73F9-4FC0-A832-48567069973A Q38834636-9D3D329A-F8DC-41FA-94BE-D836D1050BDE Q38849706-E36C093C-9C61-4E75-AE0D-83C5D76E1E6A Q38978479-C3245F9D-1A31-4D63-A49D-03C41A1FB2E0 Q39362420-F376B95A-270C-4365-A8FB-E5D569C428CF Q39488594-E8004821-7AB0-4B11-9E53-29D4DC05BF1E Q40048947-5063464E-7384-4399-877A-406B29CF5975 Q40070635-D72401DB-E7D4-4F6A-8499-9CF19F48F353 Q40072965-6B7522CE-34F1-477F-A0DA-D53847BD246C Q40073013-A9B341CD-3D95-4AD2-84C3-E60EE2EBBC42 Q40153816-692739F9-E907-4794-80C3-8820C09787D1 Q40191155-1D805DA6-856A-4462-AC4D-818A58D3579F Q40239354-22CB5951-84D3-407A-89B7-3FDFA1FB1F2B Q40281007-6DA6E175-7DDE-4E28-9407-E66C4D734717 Q42334798-E70BC0F5-97BC-458E-94CA-08B8261911B2 Q42364329-63977B39-3946-4A1E-81F8-D1AB66F3C1E4 Q42376936-5FE2081E-FEF5-4CDE-BDC5-6946BFAC5351 Q43923855-6B1557BB-6343-45AE-B32D-B43E5CB5FFFF Q46323872-FC7A65F6-1EDD-4851-B625-D9D2EEC5CE63 Q46367980-F198FA51-967D-42D4-B507-0E1EDF48321B Q46440280-03B25871-10F0-4A62-A398-DE551480FC74 Q46535667-5D9CDF26-026B-4B67-92F9-73539476CE78 Q47098854-C860AF9C-B493-449F-9CF1-164C902DB7F2 Q47107885-D2F66E8A-761C-48C5-B505-A1CE64F93283 Q47140463-03AED116-D8D2-4A57-AEFB-3C9498077C48

P2860

Effectiveness and safety of oral HIV preexposure prophylaxis for all populations

http://www.wikidata.org/entity/Q34677217

description

2016 nî lūn-bûn

@nan

2016 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Effectiveness and safety of oral HIV preexposure prophylaxis for all populations

@ast

Effectiveness and safety of oral HIV preexposure prophylaxis for all populations

@en

Effectiveness and safety of oral HIV preexposure prophylaxis for all populations

@nl

type

label

Effectiveness and safety of oral HIV preexposure prophylaxis for all populations

@ast

Effectiveness and safety of oral HIV preexposure prophylaxis for all populations

@en

Effectiveness and safety of oral HIV preexposure prophylaxis for all populations

@nl

prefLabel

Effectiveness and safety of oral HIV preexposure prophylaxis for all populations

@ast

Effectiveness and safety of oral HIV preexposure prophylaxis for all populations

@en

Effectiveness and safety of oral HIV preexposure prophylaxis for all populations

@nl

P1433

Q34677217-AA20EAD7-E26D-4F06-8947-32C126049ACC

P1476

Q34677217-D0709C1E-64F1-4407-9BD3-02ABB104A4F6

P2093

Q34677217-07CA969F-1B43-4BB7-89AB-408AF8B9C7A0

Q34677217-3991519D-F025-42AA-8E86-3FE2D3CEBFD4

Q34677217-66336194-EAB1-4DFD-91AA-4A6B1BB051E9

Q34677217-8064D3C8-BC85-49C0-AFE5-625B97B65CDB

Q34677217-D14277ED-3753-4CA7-9CA6-3356055F2F2D

Q34677217-F13E37B5-852E-4158-905D-E6994C637F5E

P275

Q34677217-7C1278CB-46CE-4368-8595-E0B642F9E1F2

P2860

Q34677217-11245397-D1D7-4935-8C48-777D3D8A1B3B

Q34677217-136B785C-F89D-402A-8D6E-785B9066E022

Q34677217-13DFBF1D-F807-4050-BE72-94C1E625D758

Q34677217-171AD29F-D5FA-4898-98FD-41099F3D0B5C

Q34677217-1ABC9550-81CB-4B90-B476-F216C0224F0F

Q34677217-1D5F88CE-35AE-4C1C-85EE-BA0FCA22DEC6

Q34677217-1ED06A18-4340-45AD-BC75-02A3CB24CF72

Q34677217-1F23CE58-E335-492E-8D4A-6EBD07054A83

Q34677217-26F2590B-6B7B-4353-86DC-203E98ED64EA

Q34677217-29A00E78-FBC8-4C86-A839-24333E9475EE

P304

Q34677217-AD70BCF5-999C-4BC6-BD12-04EDF2B3C2A2

P31

Q34677217-350C6EC7-DB70-4C89-B0DF-817082CC279A

Q34677217-6D30063E-3247-4758-851F-8215FF2DC543

Q34677217-76730dd1-8354-4843-9993-ab38171069da

P356

Q34677217-90A46A04-75C8-40E3-BEEE-73035065E558

P407

Q34677217-77BC49C7-0671-4A62-86D6-F28A93CD8C84

P433

Q34677217-412D3290-6123-41F1-AA9E-20E4B5247D62

P478

Q34677217-28E401C3-034F-41CA-8A93-787BECB1A8C8

P50

Q34677217-48887E3E-5196-4565-8BA9-3E988EB8D8CB

Q34677217-7A0BC325-D95E-4669-9A97-6C47FC591FE7

Q34677217-E73752EE-6E66-4C59-A43D-68E2DD80D6BE

P5008

Q34677217-31803A53-00C5-4F89-9739-63B63017BABB

P577

Q34677217-13348EF2-E705-4829-8687-1F1B8DAEF0AA

Q34677217-80A61158-F03F-42DE-B6EF-918EE1F00E6B

P698

Q34677217-B8549C04-40F2-482B-8ACC-8AB9CAAA98E2

P921

Q34677217-5B409280-B3A5-4B7E-BAD7-7219C715C6C8

Q34677217-EEB51CF9-D897-4DAA-B3F3-EA277CE133F8

Q34677217-F7E10414-5864-4DF6-B04D-0DD4CD0FAD22

P932

Q34677217-FC603760-E8C1-4103-8696-E17A40DA4CF1

P356

QAD.0000000000001145

P1433

P1476

Effectiveness and safety of oral HIV preexposure prophylaxis for all populations

@en

P2093

Caitlin E Kennedy

http://www.w3.org/2001/XMLSchema#string

Florence M Koechlin

http://www.w3.org/2001/XMLSchema#string

Kevin R O'Reilly

http://www.w3.org/2001/XMLSchema#string

Michelle Rodolph

http://www.w3.org/2001/XMLSchema#string

Sarah L Dalglish

http://www.w3.org/2001/XMLSchema#string

Virginia A Fonner

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Preexposure chemoprophylaxis for HIV prevention in men who have sex with men

Patterns and correlates of PrEP drug detection among MSM and transgender women in the Global iPrEx Study.

Antiretroviral prophylaxis for HIV prevention in heterosexual men and women

Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial

Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial

Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco

Safety, adherence and acceptability of intermittent tenofovir/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trial

No evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis

P304

1973-1983

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/QAD.0000000000001145

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P50

Robert M. Grant

Ioannis Hodges-Mameletzis

Rachel Baggaley

P5008

P577

2016-05-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2016-07-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27149090

http://www.w3.org/2001/XMLSchema#string

P921

human immunodeficiency virus infectious disease

Retroviridae infectious disease

preventive health services

P932

4949005

http://www.w3.org/2001/XMLSchema#string